Patients who plan to receive yellow fever vaccine during the course of the study treatment.
Patients for whom radiation therapy (RT) to the affected breast or chest wall and regional nodal areas is clinically indicated as per NCCN treatment guidelines, should receive RT after randomization when possible, and receive MK-3475 (pembrolizumab) concurrent with RT, if randomized to the experimental arm; however, RT administered, or initiated, prior to registration is also allowed; pembrolizumab may be added to ongoing radiation, or started after its completion, if randomized to the experimental arm, provided there are no > grade 2 radiation-related skin toxicities; patients who have not yet started radiation must specify at the time of screening registration whether or not they will receive RT and the extent of intended RT
Patients must be able and willing to receive prophylaxis with daily aspirin, low molecular weight heparin, factor X inhibitors or warfarin if randomized to lenalidomide; patients must also be willing to receive pneumocystis jirovecii prophylaxis with sulfamethoxazole/trimethoprim, dapsone, atovaquone or inhaled pentamidine, in the event that they are randomized to TGR-1202; patients unable or unwilling to take any listed prophylaxis are NOT eligible
Patients may receive up to a maximum of 5 days of pre-treatment with ATRA prior to administration of protocol therapy
A patient may not participate in a concurrent treatment protocol; all patients will be eligible to receive chemotherapy alone, systemic therapeutic agents, or conventional chemo-radiotherapy at the time of clinical or radiographic disease progression or at 2 weeks following completion of SBRT
Patients not able to receive standard-dose cisplatin based on the judgement of the treating medical oncologist
Patients must have measurable disease and be eligible to receive nivolumab in combination with ipilimumab treatment per institutional guidelines
Planning to receive other medical, surgical, or radiological cancer treatments during the course of this study
Unable to receive oral or IV hydration
Participants who are receiving or will receive other concurrent chemotherapies or immunotherapies for their cancer (except for patients who will receive letrozole, anastrozole, exemestane, tamoxifen, fulvestrant, trastuzumab, bisphosphonates, denosumab or ovarian suppression therapy)
Patients who receive sirolimus (Rapamune®) as part of their transplant immunosuppression regimen
Patients who are not eligible to receive paclitaxel will be allowed to receive single agent DKN-01.
Participants who cannot receive gadolinium
Patients who are otherwise ineligible to receive the antibiotics in this study
Participants who cannot receive gadolinium
Patients who receive or are planned to receive any other investigational product within the 3 weeks before the planned day for the first NKR-2 administration
Did not receive concurrent chemoradiotherapy prior to surgery
Patients planned to receive immune checkpoint inhibitor with contra-indications to receive immunotherapy
Have received vaccination against Neisseria meningitidis at least 2 weeks prior to beginning study protocol (only for cohorts where patients receive eculizumab treatment) in accordance with the most current Advisory Committee on Immunization Practices (ACIP) recommendations
Intention to receive chemotherapy within 6 months after enrollment in protocol therapy
Receive non-conventional fractionation schedules, such as stereotactic radiation (5 fractions or less) or received higher than 54 gray (Gy) delivered conventionally
Patients must be able to receive protocol chemotherapy in the judgment of the treating medical oncologist
Patients who are eligible for and willing to receive treatment with blinatumomab, inotuzumab ozogamizin, or tisagenlecleucel
Patients already receiving hypomethylating agents will be allowed to enroll on the protocol and receive concurrent treatment with vitamin C
Patients must receive insurance approval for or be willing to pay for commercial gefitinib
Patients may not plan to receive any other approved or investigational agents to treat their glioblastoma besides temozolomide prior to the evaluation visit 10 weeks after the initiation of radiotherapy and temozolomide; Note: Exceptions may be made for non-therapeutic intervention at the discretion of the principal investigator; the recently Food and Drug Administration (FDA) approved NovoTTF electric field therapy begins after the study period and is therefore permitted
Breast implant on the side of the body that will receive HIFU application
Ejection fraction < 45% will be an exclusion criteria for intensive chemotherapy; such patients may receive low intensity therapy
Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), or herpes zoster (VZV) at screening
Patients must receive a minimum dose of azacitidine of 75mg/(m)(2) dose
Willing to receive an mpMRI
Prior somatostatin analogue therapy; (patients should receive the first dose of study drug no sooner than 4 weeks from the last dose of somatostatin analogue)
As patients with ALL frequently have cytopenias, no hematologic parameters will be required for enrollment or to receive the first cycle of treatment; however, adequate recovery of blood counts will be required to receive subsequent cycles)
Patients who would have otherwise been eligible to receive routine post-RP care
Eligible for and planning to receive standard fractionated RT with concurrent TMZ
Unable to receive TKI for insurance reasons (uninsurable)
Patients who may receive the injections endoscopically should be eligible for sedation.
Patient may not receive concurrent chemotherapy with reirradiation, other than temozolomide or bevacizumab given at the discretion of the treating neuro-oncologist
For subjects being enrolled to receive PLD plus carboplatin, prior treatment with anthracyclines or anthracenodiones
Subjects in the combination therapy arms must be eligible to receive erlotinib, or nivolumab per most current prescribing information, or at the discretion of the Investigator.
Patients must agree to appropriate clinical monitoring to receive the study regimens
be considered unfit to receive chemotherapy on reason of age, concomitant morbidities, and/or residual toxicity from previous treatments, or unwillingness to receive chemotherapy. These patients must also have had a progression-free and treatment-free interval of at least 6 months after completion of the last rituximab-containing treatment. Patients in whom chemotherapy is contraindicated are defined by one of the following features:
Patient must be scheduled to receive temozolomide concurrent with and following radiation (temozolomide may be started late due to insurance reasons, insufficient counts, or other reasons)
Patients unable to receive cisplatin in the opinion of the medical oncologist
Able to receive outpatient treatment and follow-up at the treating institution.
Patients may receive radiation alone if the above criteria is not met
Patients who are unable to receive MRIs will be excluded from the study
Unable to receive prophylactic treatment for pneumocystis
EXCLUSION CRITERIA FOR REGISTRATION: subjects should not be participating in other clinical trials of interventions designed to reduce risk of ovarian cancer recurrence or plan to receive off –protocol maintenance therapy (e.g. paclitaxel or bevacizumab)
Food and Drug Administration (FDA) approval to receive compassionate use of TheraSphere
Patients in Cohort A will be randomized to receive either TIL alone or TIL plus dendritic cells
Clinically stable and eligible to receive conditioning chemotherapy
Planned to receive either primary or post-operative CRT
Planned to receive concomitant single agent chemotherapy with cisplatin given either weekly or tri-weekly
Patients must receive a myeloablative preparative regimen containing busulfan targeted to an area under the curve (AUC) of 1000/ dose for 16 doses combined with fludarabine 40 mg/M2 daily for 4 days
Patients intolerant or unable to receive these agents will be considered eligible.
Unable to receive prophylactic treatment for pneumocystis and herpes simplex virus (HSV)
Willingness to receive all outpatient treatment, all laboratory monitoring, and all radiological evaluations at the institution that administers study drug for the entire study
Patients who can only receive pentamidine therapy for PCP prophylaxis are excluded, since this drug prolongs the QT interval
Patients are eligible if they are going to receive TMZ as part of the standard adjuvant treatment regimen following concomitant TMZ/radiation therapy (RT)
As patients with ALL frequently have cytopenias, no hematologic parameters will be required for enrollment or to receive the first cycle of treatment; however, adequate recovery of blood counts will be required to receive subsequent cycles
Plan to receive anti-myeloma therapies
TREATMENT: Patients who have had prior treatment with any of the other investigational agents or combinations on this protocol are eligible but will not receive the same investigational agent (everolimus or trametinib) or combination (AZD1775/combination or veliparib/temozolomide); instead, patients will receive an investigational agent or combination prospectively identified to work on a different target in their tumor’s mutation/aberrant pathway
TREATMENT: Patients who have received prior mitogen-activated protein kinase kinase (MEK) inhibitors would not be eligible to receive trametinib DMSO on study; if these patients have mutations of interest in pathways other than the rat sarcoma (RAS) pathway, they will be eligible to receive agents based on that mutation
TREATMENT: Patients must have >=10.0 g/dL Hb and no blood transfusion in the past 28 days to receive veliparib
Patients 18-54 years of age with “good risk” AML defined as the presence of t(8;21), inv(16), or t(16;16) as diagnosed by morphologic criteria, flow cytometric characteristics, and rapid cytogenetics or fluorescence in situ hybridization (FISH) (patients with t(8;21), inv(16), t(16;16) who are unable to receive anthracycline based induction will be allowed to enroll provided the medical reason they are unable to receive anthracyclines is clearly documented and provided they fulfill all other eligibility and criteria)
Patients for whom there is a plan to receive ipilimumab, vemurafenib, or other treatment for advanced melanoma
Patients must not be receiving any other concurrent therapy considered to be investigational; patients must not be planning to receive any radiotherapy (except localized radiation for palliative care); patients must not be planning to receive any concurrent chemotherapy, immunotherapy, radiotherapy or other treatment with curative intent
Patients who are carriers of hepatitis B will be included in this study; these patients are not eligible to receive rituximab as a component of their chemotherapy mobilization
Residual areas of limited disease should receive radiotherapy following and not prior to transplantation
Participants must have V20 (volume of lung to receive 20 Gy radiotherapy according to simulation) < 35%.
Patients must be able to receive weekly cisplatin
Consultation, agreement, and documentation in the patient’s chart by a radiation oncologist that patient is suitable to receive radiotherapy per this protocol
Have additional uncontrolled serious medical or psychiatric illness that in the point of view of the investigator can render the patient unable to receive therapy or make it unsafe to receive therapy.
Be considered ineligible to receive cisplatin-based combination therapy, based on protocol-defined criteria.
Subjects may be eligible to receive MK-3475 in the second course phase of this study if the study remains open and the subject meets the following conditions:
Did not receive any anti-cancer treatment since the last dose of MK-3475
Patients must not have plans to receive concomitant chemotherapy, other biological or immune therapies, or radiation therapy for the treatment of prostate cancer during the period of study treatment
Plans for the patient to receive other concomitant local therapy (including standard fractionated radiotherapy and surgery) while on this protocol except at disease progression
Age > or equal to 60 years; patients younger than 60 who are unsuitable for or unwilling to receive standard cytotoxic chemotherapy are also eligible to be enrolled
Inability to receive a port or peripherally inserted central catheter (PICC) line
Unable to receive oral or IV hydration
Able to receive ibrutinib through commercial supply, i.e., insured patients meeting Food and Drug Administration (FDA)-approved indications
Patient is unable to receive IV contrast
Patients with 17p deletion can only be enrolled on Arm C; these patients will receive the expanded T cells without lymphodepleting chemotherapy
Patients should have no contraindications for chemotherapy or radiation, and should receive either definitive chemoradiation therapy or preoperative chemoradiation therapy
Is unable to receive a port or peripherally inserted central catheter (PICC).
Any Chronic Myeloid Leukemia disease phase, as long as the patient is unable to receive treatment with imatinib, dasatinib and/or nilotinib for any reason.
Unable to receive prophylactic treatment for pneumocystis
Eligible to receive treatment with the selected doublet-chemotherapy
In the opinion of the investigator, patient must be able to receive at least 2 cycles of treatment
Planning to initiate adjuvant or neoadjuvant anthracycline (AC) chemotherapy (doxorubicin [doxorubicin hydrochloride] 60 mg/m^2 and cyclophosphamide 600 mg/m^2 every 2-3 weeks x 4 cycles)\r\n* Note: \r\n** Participants may be planning to receive additional adjuvant therapy after the completion of AC chemotherapy\r\n** Receipt of all standard chemotherapy and/or targeted therapy regimens after AC that deemed clinically appropriate by the treating physician are permitted; for example, patients may receive taxanes or carboplatin/paclitaxel; Her2 positive patients may receive trastuzumab with or without pertuzumab\r\n** HER2 positive patients must be planning to initiate trastuzumab therapy after AC chemotherapy
Patients with known active central nervous system leukemia should be excluded from this clinical trial; patient receiving intrathecal chemotherapy prophylaxis should not receive pomalidomide for >= 3 days after administration
Treatment Naive only: and a) do not want to receive chemoimmunotherapy or b) have comorbidities that would preclude chemoimmunotherapy.
Willingness by subject to be randomized to receive either ofatumumab or duvelisib at the dose and schedule defined in the protocol
Unable to receive prophylactic treatment for pneumocystis or herpes simplex virus (HSV)
Unable to receive background chemotherapy based on prior treatment history and cardiac function
Patients must have CA125 level >= 10 to participate in the immunotherapy aspect of the trial and receive oregovomab; if the patient has CA125 >= 10 who is not eligible to receive oregovomab (e.g. allergic to the drug) but is eligible for the rest of treatment, this patient should be accrued to the part of protocol without oregovomab
Subjects who are anticipated to receive a transplant within the first 6 months of treatment on trial
Eligible for and planning to receive maintenance temozolomide after completion of definitive radiotherapy plus temozolomide
Patients will be excluded if they are not planning to receive concurrent temozolomide
Patients must receive RT at the participating institution.
Unable to receive or previously intolerant of moderate and/or deep sedation
Subjects with mycosis fungoides (MF) and a known history of non-complicated staphylococcus infection/colonization are eligible provided they continue to receive stable doses of prophylactic antibiotics
Staging laparoscopy is not required at the outset of the trial, including in patients who might otherwise receive staging laparoscopy per National Comprehensive Cancer Network (NCCN) guidelines (high-risk body and tail lesions), because patients will receive systemic chemotherapy at equivalent dose to patients who have documented stage IV disease
Patients with central nervous system involvement by APL are eligible and may receive concomitant treatment with radiation therapy and/or intrathecal chemotherapy in accordance with standard medical practice
Patients may receive any number of cycles of chemotherapy prior to treatment with SBRT, but not within 2 weeks of the first fraction of radiotherapy (RT); patients are not required to receive any chemotherapy to be eligible for study enrollment
Age greater than or equal to 1 but less than or equal to 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive total body irradiation (TBI) may receive reduced intensity regimen 3
Able to receive antibiotic prophylaxis against N. meningitides for the duration of the study.
Patients who cannot receive cyclophosphamide
Inability to receive TBI.
Subjects must be able to receive outpatient treatment and laboratory monitoring (where specifically indicated) at the institution that administers study drug for the entire treatment period
Pts with NSCLC who have received, are receiving or are planning to receive two to four cycles of standard frontline chemotherapy are eligible; choice of chemotherapy is at the discretion of the medical oncologist; concurrent chemoradiotherapy will not be permitted during the active study period; post-operative radiotherapy can be administered as clinically indicated
Patients aged >= 80 are not excluded; however, candidates in this age group should be thoroughly evaluated before enrollment in the study, to ensure they are fit to receive chemotherapy, and to potentially undergo pancreaticoduodenectomy; in addition to meeting all of the baseline patient selection criteria, clinical judgment on their susceptibility to infection and expected stability of their performance status and suitability to receive intensive chemotherapy cycles, should be paid special attention to; patients should not be enrolled in the study should there be any hesitation on any of these considerations; baseline criteria for all patients enrolled on the study must be carefully evaluated and all criteria followed appropriately
Concomitant chemotherapy and radiotherapy while on protocol is prohibited; prednisone therapy will not be permitted with the exception of brief courses (=< 14 days) used for inflammatory conditions unrelated to CLL; patients may receive intravenous immunoglobulin (IVIG) while on protocol; patients may receive erythropoietin, darbepoetin, filgrastim, peg filgrastim, or sargramostim while on protocol; patients with cellular immune cytopenias may receive cyclosporine (pure red cell aplasia, etc.) while on study but consultation with principal investigator (P.I.) (or designee) is required
Patients must be able to receive proton radiation treatment
Unable to receive medications by mouth
Patient’s must be eligible to receive melphalan dose of 200 mg/m^2
Patients are not allowed to receive prior surgery or chemotherapy for the IHC
Patient understands if he or she is randomized to receive molecularly guided treatment, they must meet all inclusion and exclusion criteria in the drug specific appendix for which they were randomized
Unable to receive medications by mouth
Planned to receive standard cisplatin chemotherapy administered either weekly or every third week.
Planned to receive 4 to 6 cycles of pemetrexed or gemcitabine in combination with cisplatin or carboplatin • For subjects to receive pemetrexed, planned to receive vitamin B12 and folate per pemetrexed approved labeling
Patients who are not appropriate to receive more intensive chemotherapy in the judgment of the investigator
Patients should receive concomitant therapy with bisphosphonates, regardless of the presence of bony lesions, although study physicians may use their discretion based on presence of renal insufficiency or other mitigating factors
Have undergone surgical, medical and radiation oncology evaluations to confirm:\r\n* Eligible for infusional fluorouracil (5-FU) or capecitabine\r\n* Will not undergo surgery for the study disease\r\n* Able to receive HDR brachytherapy
Patients may receive estrogen +/- progestin replacement
Patients may receive transfusion if necessary to reach the pre-apheresis hematology parameters; if elevated PT is concluded to be due to a circulating anticoagulant then patient may enroll despite the abnormal laboratory finding
May not receive chemotherapy until valacyclovir completed
Women who receive Oncotype Dx testing
Have an email address at which to receive CaringGuidance prompts
Newly diagnosed patients with stage 1 through 3a BC scheduled to receive a 12-week, 16-week, 18-week, 20- week, or 24-week chemotherapy regimen, adjuvant or neoadjuvant
Are receiving, or are likely to receive another intervention for the treatment of fatigue during the study period; (per provider report)
Patients intolerant to prior immunotherapy (unable to continue/receive due to immune-related AE).
Scheduled to receive RT with curative intent with the expectation that some portion of the mucosa of the upper aerodigestive tract will receive a dose of at least 50 gray.
PATIENTS: Diagnosed with a primary HNC and going to receive at least 4 weeks of RT with at least 20 fractions.
Patient is planned to receive interventional procedures (i.e. surgery) that may affect study outcomes
Participants must live within 35 miles of the University of Washington, Seattle, WA to receive the in-person version of the intervention
Patients who plan to receive chemotherapy at Dana-Farber Cancer Institute (DFCI) to treat recurrent, incurable gynecologic cancers (i.e., ovarian, uterine, and cervical that has recurred despite >= 1 prior treatments)
Patient’s oncologist advises against the trial – in which case they can choose to receive stimulation with letrozole + gonadotropin
PATIENTS: Planning to receive ongoing care from a participating oncologist.
Planning to receive first-line chemotherapy at Massachusetts General Hospital (MGH)
Planning to receive care at MGH
Eligible to receive, but not yet begun, aromatase inhibitor therapy
Participants must be willing and able to receive email newsletters via computer or smartphone for 12 months’ AND/OR willing and able to receive texts via cellphone for 12 months\r\n* Participants must have a personal email address to receive newsletters\r\n** If a participant does not have an email address but has access to a smartphone or a computer, at the baseline data collection visit Columbia University Medical Center (CUMC) study staff will create a free personal Google Gmail email account.
There must be no plans for the patient to receive other concomitant therapy while on this protocol treatment (other than sandostatin or BIS-phosphonate therapy)
Planning to receive ongoing care from a participating oncologist and willing to be seen at least monthly
Refusal to receive NIPPV
Patients anticipated to receive radiation therapy with protons
Failed to receive satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current depressive episode
Will receive radiotherapy of cranium within one week prior to or during the study
Patients MUST also be ready to receive a cycle of chemotherapy that predictably renders neutropenia at least 70% of the time OR has a risk of febrile neutropenia of at least 20%; this can be any cycle number; it does NOT need to be the FIRST cycle of chemotherapy they are to receive; it is also OK if the patient will be getting granulocyte stimulation factor support; however, if the patient meets above criteria and the chemotherapy he/she will receive causes neutropenia 70% of the time or confers a risk of febrile neutropenia of at least 20%, but is not listed, please contact study Karen Moody, MD, overall study principal investigator, for clarification of eligibility
PATIENTS ONLY: Diagnosed with a primary glioma and going to receive at least 4 weeks of radiotherapy with at least 20 fractions
Unable to receive R-CHOP chemotherapy
Inability to receive lumbar intrathecal injection because of other factors
Patients scheduled to receive broad-spectrum prophylactic antibacterial therapy are ineligible; patients only receiving prophylaxis for Pneumocystis pneumonia (PCP) (trimethoprim [TMP]/sulfamethoxazole [SMX]) or encapsulated organisms (penicillin) are eligible
Patients using prophylactic antimicrobial locks in the CVC at the time of enrollment and those who are scheduled to receive antimicrobial locks in the CVC as part of a treatment plan are ineligible
Treatment plan to receive standard cisplatin monotherapy administered either every three weeks (80-100 mg/m2 for 3 doses) or weekly (30-40 mg/m2 for 6-7 doses). The decision on which chemotherapy regimen to use in combination with IMRT and GC4419 will be at the discretion of the investigator.
Participant must plan to receive follow up care at Dartmouth-Hitchcock
Prospective study: completed primary treatment for breast malignancies; receive survivorship care at Thomas Jefferson University (TJU) or Reading Health System (RHS)
Receiving or planning to receive outpatient therapy for any cancer
Own a smartphone (in order to receive text messages and utilize the phone app)
Agree to receive text messages on their smartphone over a 3-month period
The patient cannot receive text messages
PATIENT: Planning to receive all medical care for cancer at the enrolling institution
Are unwilling to receive intensive (e.g. 7+3) chemotherapy, or
Patients ?60 years unfit to receive intensive (e.g., 7+3) chemotherapy who have:
Allergic to selinexor or any of the chemotherapy intended to receive
No prior renal disease that in the opinion of the attending physician would make the patient ineligible to receive the study drug
Patients may receive up to 2 doses of aerosolized ribavirin (modified regimen) before enrollment into the study
Planning to receive care at the participating institution
Plan to receive or is receiving primary frontline anti-myeloma therapies
Subjects are to receive autologous PBSC transplant following mobilization, CD34+ cells collected by apheresis, and conditioning chemotherapy
Plan to receive any RBC transfusion between randomization and study day 1.
Have a plan to receive a standard cisplatin chemotherapy regimen administered weekly (30-40 mg/m2) or approximately every 21 days (80-100 mg/m2)
Patient must have a valid mailing address within the United States to receive study materials
Able and willing to receive phone calls
Patient is expected to receive 2 weekly doses of vincristine as outlined by the Total XVI or “as per TOTXVI” protocol while on study drug (i.e. no known dosage reductions or planned missed doses)
Subjects who are planned to receive > 2 mg flat dose of vinca alkaloids
Women must have a cervix to receive cervical cancer screening
Patients aged 50-74 with no evidence of a colonoscopy within 9 years or fecal testing within 11 months, and no history of colorectal disease will be eligible to receive a mailed FIT.
Patients must not be expecting to receive radiation or additional chemotherapy
Patient is receiving or plans to receive other investigational therapy during study.
Owns a cell phone that can receive text messages and is willing to receive text messages for this study
Patients should receive their definitive treatment at Wake Forest University (WFU) Cancer Center or at Medical University of South Carolina (MUSC) Cancer Center
Patients who receive RT or CRT with palliative intent
Ability to send and receive emails
PILOTS I, II AND III: Have a cellular telephone and are able and willing to send and receive text messages
At screening has suspected or confirmed CDI, and is receiving or is planning to receive a 10- to 21-day course of antibacterial drug treatment for CDI
Willing and able to receive weekly phone “check-ins” from a study coordinator
Patient planned to receive altered fractionation radiotherapy or multiple fractions per day
Own a phone that has texting ability and free texting or be willing to receive a phone from study staff
Are willing to receive and respond to text messages from the study teams, throughout the duration of the study
Willing to receive anti-epileptic prophylaxis for the duration of study drug administration.
Willing to receive anti-epileptic prophylaxis for the duration of study drug administration
Subject has a history of central nervous system radiotherapy that encompasses all or part of the cochlea or will receive such radiation therapy during the course of the study.
Has had benzodiazepine, opioid or opioid like therapy initiated within 48 hours prior to study drug administration, or is expected to receive within 120 hours following initiation of chemotherapy except for single doses of midazolam, temazepam or triazolam
Received the following within 7 days before screening or plans to receive during the study: ganciclovir, valganciclovir, foscarnet, acyclovir, valacyclovir, or famciclovir
Patients who have received an investigational drug in the 30 days before CEUS, or will receive one within 72 hour after their CEUS exam
Cannot receive furosemide
Cannot receive furosemide
Patients who will receive radiotherapy as treatment for left-sided breast cancer
Patients with an estimated GFR (eGFR) > 90 ml/min reported within 30 days, and who have not had intervening chemotherapy or other treatment or condition that might deteriorate renal function, may receive any gadolinium agent
Patient must be planning to receive chemoradiation therapy with cisplatin
Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), and herpes zoster (varicella zoster virus [VZV]) at start of treatment
Patients meeting the criteria for enrollment on research protocol 11-016 to receive DSTP3086S antibody drug conjugate (ADC) (the therapeutic ADC based on MSTP2109A) will be preferred patients for this study; patients that are to receive DSTP3086S will not be injected with DSTP2086S until imaging with 89Zr-DFO-MSTP2109A is finished, approximately 1 week
Had or plan to receive any chemotherapy
Planned treatment with standard agents or investigational agents that can potentially activate herpesvirus TK, including but not limited to the following; concurrent radiation therapy is permissible:\r\n* Platinum compounds (for example, cisplatin, carboplatin)\r\n* Anthracyclines (for example, doxorubicin or pegylated doxorubicin)\r\n* Tubulin disrupting agents (for example, vincristine, vinblastine)\r\n* Rituximab\r\n* Gemcitabine\r\n* Cytarabine\r\n* Histone deacetylase inhibitors\r\n* Bortezomib; Note: patients who would not receive bortezomib as part of their usual care may receive a one-time dose of bortezomib for the purpose of imaging with 124I-FIAU and FIAU-PET-CT
Patients must be planning to receive one of the study-allowed regimens as their initial treatment for their current disease; myelosuppressive therapy must follow the standard regimen, although a dose reduction of up to 10% is permitted; this treatment may be neoadjuvant or adjuvant chemotherapy; patients must not be receiving or planning to receive concurrent radiation during systemic treatment
Referred from one of the above six centers, or chooses to receive care at one of the six centers
PHASE I: Women who state that there are still deciding on breast cancer treatment (e.g., whether or not to take hormone therapy or to receive radiation treatment)
Owns a cell phone that can receive text messages and is willing to receive text messages for this study
Patients must have interest in a legal consultation as specified by the I-Help model to receive free legal consultation.
